What we use astatine for
Where does it go, and why this element?
Only for research. The Royal Society of Chemistry says that there are no uses for astatine outside research3. Most of this research is on astatine-211 as a cancer treatment. Its alpha particles travel only a few cell widths, so they can kill cancer cells and spare nearby tissue.
Last updated 14 October 2026.
Where it goes
All astatine goes to laboratories and clinical trials. We found no world breakdown. One producer, the University of Washington, published where its astatine-211 went in an average year from 2018 to 2021. About 76% went to three clinical trials and 20% to chemistry and preclinical studies. About 4% went to other US researchers1.
Only two clinical trials were complete when a review was published in 20232:
- Duke University, 1998 to 2001. Eighteen patients with recurrent brain tumors received an astatine-211 antibody in the cavity left by surgery23. No dose-limiting toxicity was recorded2.
- Gothenburg, Sweden, 2005 to 2011. Twelve women with recurrent ovarian cancer received an astatine-211 antibody in the abdomen2.
The authors of the same review counted seven trials under way, five of them at the Fred Hutchinson Cancer Center in Seattle2. In 2025 an Osaka team reported a trial of sodium astatide in 11 patients with thyroid cancer. Three of the six patients at the highest dose had dose-limiting effects on their blood cells4. The authors call the treatment well tolerated, with preliminary signs of efficacy4. The company Alpha Fusion helped to fund that trial4. In 2024 the University of Osaka announced a second trial, of an astatine-211 drug for prostate cancer that resists standard treatment5.
All these trials were small and tested safety or dose. None had a control group2. We found no approved astatine medicine.
Why this element
Astatine-211 emits alpha particles. In tissue they travel only about 50 micrometers, a few cell widths3. Feng and Zalutsky write that fewer than 10 atoms bound to a cell can kill it6.
The authors of the 2023 review give more reasons. Each decay gives one alpha particle, and there is no long chain of radioactive daughters2. The half-life of 7.2 hours is long enough for a three-hour trip from the cyclotron, and short enough to limit exposure of normal tissue2.
Astatine is a halogen, like iodine. Like iodine, it collects in the thyroid gland7. That is why the Osaka team tests it against thyroid cancer that no longer responds to radioactive iodine. In Japan, high-dose radioactive iodine treatment needs a stay in a shielded room. In the Osaka trial, patients could leave the treatment area after the injection4.
What could replace it
Other alpha emitters compete with astatine-211 for the same job. The authors of the 2023 review name thorium-227, radium-223, lead-212, bismuth-212 and actinium-2252. They write that these have long decay chains and may suffer from recoil problems2.
For thyroid cancer, astatine-211 competes with radioactive iodine (iodine-131). The Osaka team describes astatine-211 as a possible alternative to it4.
Where demand is going
The authors of the 2023 review state that about 30 production sites are working or will soon be available2. Japan built a supply chain from five production sites to more than 18 users2.
Until 2025, all trials were led by universities and hospitals8. In October 2025 Alpha Fusion announced a supply system with a Kobe hospital for what it expects to be the first company-sponsored trial8. In February 2025 Framatome and IBA agreed to work on a network of astatine-211 cyclotrons in Europe and the United States9. In June 2026 IBA launched a cyclotron that is made only for astatine-211 production10.
In 2022 the University of Washington reported that some companies want to see clinical responses before they invest1. No source we read gives a forecast of demand in becquerels or doses.
Sources
- 1
Yawen Li and others, University of Washington (slides), 2022. Astatine-211 DOE Isotope User Group Meeting 2022 , Slides 'At-211 Production and Research in the U.S.' and 'Yearly At-211 Production at UW'.
Yearly production at the University of Washington and where it went; cost as a hurdle.
-
~90 mCi (4%) to other U.S. investigators ... ~440 mCi (20%) for chemistry and preclinical studies ... ~1.7 Ci (76%) for three on-going clinical trials
-
~90 mCi (4%) to other U.S. investigators
-
~440 mCi (20%) for chemistry and preclinical studies
-
~1.7 Ci (76%) for three on-going clinical trials
-
some want to see clinical responses before they will invest
-
- 2
Per Albertsson and others (Frontiers in Medicine 9:1076210), 2023. Astatine-211 based radionuclide therapy: Current clinical trial landscape , Sections 1 to 4; tables 1 and 2.
Natural abundance, why astatine-211 suits therapy, completed and ongoing clinical trials, production sites, other alpha emitters, supply networks.
-
Only two clinical trials have been performed to date
-
This phase I dose escalation study (NCT00003461) was performed between April 1998 and June 2001
-
No dose-limiting toxicity was recorded
-
From February 2005 to March 2011, 12 patients with recurrent ovarian cancer were treated
-
presently, seven different protocols are underway
-
There are five early phase clinical protocols with 211 At-based radionuclide therapy at the Fred Hutchinson Cancer Center in Seattle
-
To date, all performed and scheduled trials are small safety or dose-finding trials, and none have a control population.
-
has a 100% alpha emission with only one alpha particle emitted per decay
-
which may decrease normal tissue exposure, while still being long enough to be shipped for up to 3 h
-
This is comparable to other alpha emitters such as thorium-227 ( 227 Th), radium-223 ( 223 Ra), lead-212 ( 212 Pb), bismuth-212 ( 212 Bi), and actinium-225 ( 225 Ac)
-
all of which have a long decay series and may suffer from recoil problems
-
Approximately 30 production sites are or will shortly be available
-
the creation of a nationwide supply chain from five 211 At production facilities to more than 18 end-user facilities
-
- 3
Royal Society of Chemistry, 2025. Astatine, in the Periodic Table .
Uses, biological role, the 1939 and 1940 claims, and the podcast 'Chemistry in its element: astatine' by Mark Peplow, with the Greenwood and Earnshaw estimate of astatine in the crust.
-
testing astatine radiotherapy in 18 brain tumour patients
-
can only travel about 50 micrometers in tissue
-
There are currently no uses for astatine outside of research.
-
- 4
Tadashi Watabe and others (Journal of Nuclear Medicine 66:1941-1947), 2025. First-in-Human Study of [211At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial) .
Results of the Osaka trial, production at RIKEN, and outpatient treatment.
-
Dose-limiting toxicities occurred in 3 of 6 patients who received 3.5 MBq/kg
-
Targeted a-therapy with [211At]NaAt was well tolerated and showed preliminary efficacy in patients with RAI-refractory DTC
-
This study was funded by the AMED Clinical Research and Trial Promotion Research Project (grant 23lk0201139h0003) and Alpha-Fusion, Inc.
-
In many countries, including Japan, high-dose RAI therapy with [131I]NaI requires inpatient isolation in specialized radiation treatment rooms
-
Isolated hospitalization in a dedicated room was not required
-
211At, a cyclotron-produced a-emitter, has attracted interest as a potential alternative to radioactive iodine (RAI) because of its superior cytotoxic properties.
-
- 5
Graduate School of Medicine, University of Osaka, 2024. First in-human investigator-initiated clinical trial to launch for refractory prostate cancer patients: Novel alpha therapy targets prostate-specific membrane antigen .
The start of the Osaka trial of astatine-211 PSMA-5 in prostate cancer, and a new cyclotron for astatine at Osaka.
-
A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients
-
- 6
Yutian Feng and Michael R. Zalutsky (Nuclear Medicine and Biology 100-101), 2021. Production, purification and availability of 211At: Near term steps towards global access , Sections 3, 5, 6, 7 and 10; table 1.
The production route, the 13 production sites and their output, the limits to supply, distribution networks and dose estimates. Read with Firecrawl (author manuscript on PMC).
-
with effective killing achievable with less than 10 atoms bound per cell
-
- 7
Los Alamos National Laboratory, 2025. Astatine, in the Periodic Table of Elements .
The 1940 synthesis and its reaction, the amount on Earth, the half-life, uses and health.
-
Like iodine, astatine accumulates in the thyroid gland.
-
- 8
BioSpectrum Asia, 2025. Japan's Alpha Fusion and Kobe City Medical Center General Hospital establish At-211 investigational drug supply system .
The supply system for the first company-led trial of an astatine-211 drug in Japan.
-
resulting in all clinical trials to date being academia-led
-
what is expected to be the world’s first company-sponsored clinical trial using At-211
-
- 9
IBA RadioPharma Solutions (press release), 2025. Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in Europe and the USA .
The memorandum between Framatome and IBA and the planned pilot plant in France.
-
The first milestone in this collaboration will be the establishment of a dedicated production pilot facility, set to be installed by 2027-2028.
-
- 10
IBA (press release), 2026. IBA launches Cyclone iKure, a cyclotron designed for industrial scale Astatine-211 production .
The launch of a cyclotron made for astatine-211 production, 1 June 2026.
-
a dedicated cyclotron for routine Astatine-211 (At-211) production
-